Gene therapy trial for diabetic macular edema (DME)
Part of Eyes & vision clinical trials.
This trial tests a gene therapy for diabetic macular edema (DME), a condition where fluid builds up in the central part of the eye's retina. It aims to improve vision and reduce the need for frequent eye injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 74 years old.
- You have been diagnosed with clinically significant diabetic macular edema (CI-DME).
- Your vision in the study eye is between 24 and 73 letters on a standard eye chart (roughly 20/320 to 20/40).
- You do not have any other eye disease in the study eye that could affect your vision or require treatment during the trial.
- You are willing and able to follow the study instructions and appointments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage (Phase 1) study tests a new gene therapy to improve vision for adults with diabetic macular edema. It mainly looks at whether the treatment can be safely given and may help your vision over time.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This trial tests a gene therapy called RGX-314 for people with diabetic macular edema that affects the center of the vision. If you have had previous treatment and still have swelling, this study may be an option.
This trial tests an investigational drug called CU06-1004 for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). It aims to see if the drug can improve vision and reduce swelling.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This early-phase trial tests a new implant (EC-104) that goes inside the eye to treat diabetic macular edema (DME), a condition that causes blurry vision from fluid buildup. The implant slowly releases medicine over time, and the study will see if it is safe and helpful for people with DME.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.